Study title | Conditions | Interventions | Study type and phase |
---|---|---|---|
Plasma microRNA, lung cancer | Lung cancer | Screening | Interventional study, not applicable |
MicroRNA-155 and telomerase reverse transcriptase, non-muscle invasive bladder cancer | bladder cancer and disease | Diagnostic method: miRNA -155 Diagnostic method: Human telomerase reverse transcriptase | interventional, not applicable |
Plasma microRNAs, pelvic gynecologic tumors | Ovarian cancer Endometrial cancer | Other: blood sample | Interventional study, not applicable |
Circulating miRNAs, breast cancer | Breast cancer | Drug: tamoxifen, letrozole, anastrozole, exemestane | Interventional study, Phase 4 |
A 6 microRNA Tool for Stratifying Stage II colon cancer | Colonic Chemotherapy | A 6 microRNA stratified tool | Interventional study, Not applicable |
MicroRNA in NAF, serum, and tissue, breast cancer | Breast Cancer Ductal carcinoma in situ | Drug application: intranasal oxytocin | Interventional study, Phase 2 |
A multicenter phase I study of MRX34, MicroRNA miR-RX34 liposomal injection | Primary liver cancer SCLC Lymphoma | Drug application: MRX34 | Interventional study, Phase 1 |
MicroRNA involved in cutaneous squamous cell carcinoma | Cancer of the Skin | Genetic: arm A | Interventional study, not applicable |
Plasma miRNAs for Predicting Radiosensitivity in Advanced Non-small Cell Lung Cancer | Advanced non-small cell lung cancer | Radiotherapy | Interventional study, not applicable |